📸 From the #PROS session at #SIOPcongress: #Craniopharyngioma – Management and Complications Exploring surgical and radiotherapy strategies, long-term complications, and multidisciplinary care in pediatric patients. Stay tuned for more session highlights!

Interpreting liver mets on MRI can be challenging, in part b/c imaging features (hypo vs hypervascularity) vary by primary tumor site. I adapted this slide from Dr. Jim Apisarnthanarax presentation at ASTRO. Important for diagnosing & if treating w MR-guided RT.

Jeff Ryckman Dr. Nina Niu Sanford Ted Yanagihara, MD, PhD Shankar Siva William A Hall, MD 3 tier RECIST-Kidney SABR Stable/reassuring (stable on max dimen/3-D volume, no new enhancement) Responding (>30% decrease 2-D max dimension/3-D volume and no new enhancement) Progressive; >20% increase in 2-D max dimension/3-D volume, new enhancement

Jeff Ryckman Dr. Nina Niu Sanford Ted Yanagihara, MD, PhD Shankar Siva William A Hall, MD It’s quite common to get called as progression based on contrast. Case below treated 42/3 with SABR for T3a disease. Still contrast enhancement 7 years post.

Thank you to everyone who attended the ABS Brachytherapy #Prostate and #GYN Workshop! Your engagement and expertise made it a truly impactful event. We’re grateful for your commitment to advancing #brachytherapy. #AllThingsBrachytherapy DrKamrava Junzo Chino

Who was the first #radonc patient treated with a linear accelerator in the US and when? Gordon Isaacs, at Stanford, in 1957. visualsonline.cancer.gov/details.cfm?im…

Enjoyed co-leading liver SBRT workshop & nice to see how ROs practice globally. In US, SBRT constrained to 5 fx (billing, pt convenience), but in Germany 7, 12 fx often used. Table shows how more fx maintains ablative dosing to tumor (BED10) but spares normal tissues (EQD23).

Oh my goodness, the dedication that took. 😭

✨ A standout moment at #SIOPcongress! Incoming #PROS President, Arnold Paulino , delivering the inspiring D’Angio Lecture: “What does the dragon have to do with radiotherapy?” Thanks to Dr. Mark Gaze (UK) for moderating this inspiring session.

Another outstanding concurrent sessions with lectures and proffered papers on CNS and GI cancers #RANZCR2025 arjun sahgal Simon Lo Dr. Nina Niu Sanford Gkika Eleni Simon Boeke RANZCR

The optimal management of oligometastatic HNSCC is a debated and important question. How can we improve *overall survival* in this more favorable population? EA3211 is a phase III randomized trial studying this exact issue. Enrollment is even more streamlined with the most

I’m not privy to his clinical details so can’t fully comment but feel that the data supports RT in de novo mHSPC (regardless of volume of ds) PEACE-1 showed RT improved time to mCRPC and GU adverse events (and OS if not getting ARPI)

EMBARK: Overall survival with enzalutamide in biochemically recurrent #ProstateCancer Presented at #ESMO25 cslide.ctimeetingtech.com/esmo2025/atten… Enzalutamide plus leuprolide significantly improves overall survival and delays disease progression compared with leuprolide alone in high-risk

It’s with deep sadness that we share the unexpected passing of our daughter and sister, Emman. She brought so much joy, laughter, and love into our lives and into the lives of everyone who knew her. Emman had a way of making people feel seen and heard, and she wasn’t afraid to

The final results from the phase III TRILYNX study recently dropped, comparing X+CRT with CRT in HPV-negative HNCC, and not only was it negative but it suggested worse toxicity AND disease-control outcomes with xevinapant. ascopubs.org/doi/10.1200/JC…

Dr ⁦Neha Vapiwala⁩ sharing insights into the importance of multidisciplinary and collaborative #research as we in #radonc advance our role in the care of #patients with #prostate #cancer #pcsm ☢️ ⁦ASTRO⁩ ⁦Prostate Cancer Foundation⁩ ⁦PCF Science⁩ #PCFRetreat25

Should we think about 3 tier SABR response following kidney SABR? Shankar Siva Chad Tang, MD Jeff Ryckman Nicholas Zaorsky, MD MS I am just liking this initial version which I just put together for a recent talk. May be adding “reassuring” for non-progressive

#RANZCR2025 rad onc trainees sessions on local and international fellowship opportunities at Radiation Oncology Sunnybrook Health Sciences Centre University Health Network Peter Mac Radiation Oncology The Alfred Cristian Udovicich Therese Kang Dr. Andrew Loblaw arjun sahgal

#RT utilization rate for #CTCL only 29% over all treatment lines. Unexpectedly lowest in highly accessible areas; no distance-decay association. Geographic disparities in diagnosis & RT-utilization rates may relate to dermatologist & linac availability ➡️ redjournal.org/article/S0360-…

Great to see the updated BCLC guidelines include RT! RT now incorporated into most major guidelines for HCC (BCLC, AASLD, EASL, NCCN, others) & should be a standard of care option. Full link here: sciencedirect.com/science/articl… OncoAlert